RxDoctor Payments Data

Travis Pagliara, MD

Urology · Minneapolis, MNNPI 1942597208

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $37,925 of the $52,512 with a category attached, or 72.2%. Boston Scientific accounts for 92.2% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $14,962, 3.5 times the $4,302 reported in 2019. Among urology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,512in general payments, 2019–2025

Across 70 payments — averaging $750.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$48K
  • Coloplast$2K
  • Gyrus ACMI, Inc.$2K
  • Calyxo, Inc.$213
  • AstraZeneca$35
  • Axonics, Inc.$34
  • plus $38 from 2 others

What the payments were for

  • Consulting fees$13,63826%
  • Speaking & faculty fees$37,92572%
  • Food & beverage$9032%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,512 in reported general payments places this provider in the 90th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$27,185
Medicare patients
96
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron46$23,110
Trospium Chloride ErTrospium Chloride19$1,965
Finasteride59$554
Tamsulosin Hcl56$539
Solifenacin Succinate13$135
Levofloxacin11$120
Oxycodone Hcl36$87
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$80

Paid to pharmacies, not to this prescriber.

Other urology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →